Dr. Caroline MacCallum

MD, FRCPC (Internal Medicine), BSc Pharm

Clinical Instructor, Department of Medicine  |  University of British Columbia
Adjunct Professor, Faculty of Pharmaceutical Sciences  |  University of British Columbia
Associate Member, Division of Palliative Care  |  University of British Columbia
Medical Director, Greenleaf Medical Clinic
Special Interest: Complex Pain & Cannabinoid Medicine

Dr. Caroline MacCallum is a specialist in internal medicine, with expertise in complex pain and cannabinoid medicine. She is a clinical instructor in the Department of Medicine; Adjunct Professor in the Faculty of Pharmaceutical Sciences program; and associate member in the Dept. of Palliative Care at the University of British Columbia.

Dr. MaCallum is the medical director of Greenleaf Medical Clinic, where she has assessed and developed cannabinoid treatment plans for more than 5,000 patients using legal medical cannabis approved by Health Canada.

Caroline MacCallum is the primary author of Practical Considerations for Medical Cannabis Administration and Dosing, published in the European Journal of Medicine. She is the assistant editor for the upcoming Cannabinoids and Pain book by Springer; and first author on eight chapters pertaining to cannabis pharmacovigilance including: mental health, impairment, dosing, patient safety (contraindications & drug interactions), product safety, pain, and cannabis-opioid synergy.

Dr. MacCallum has presented internationally on the topic of cannabis dosing, safety and polypharmacy reduction/substitution. She has qualified as a medical cannabis expert and testified in arbitration for a claim involving a challenge to Health Canada’s 24-hour rule for cannabis impairment. Dr. MacCallum is currently working with university research groups, hospitals, health benefit programs, provincial and national committees to create; guidelines, safe prescribing practices, clinical trials, patient registries and adverse event monitoring.

Her research interests include: cannabis and psychedelics as adjuvants to standard of care and for deprescribing/drug substitution; pharmacovigilance and impairment; and symptomatic and functional improvement in complex conditions with particular focus on fibromyalgia, chronic fatigue, PTSD, TBI and chronic pain. Dr. MacCallum has also recently co-authored a review on Ketamine for assisted psychotherapy (KAP) for mood disorders.


Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine. 2018;49 – https://doi.org/10.1016/j.ejim.2018.01.004

Canadian clinical practice guidelines for the use of plant-based cannabis and cannabinoid-based products in the management of chronic non-cancer pain and co-occurring conditions: protocol for a systematic literature review. BMJ Open. 2020;10:e036114 – http://dx.doi.org/10.1136/bmjopen-2019-036114

Characterization of mental health in cannabis dispensary users, using structured clinical interviews and standardized assessment instruments. BMC Psychiatry. 2019;19:335 – https://doi.org/10.1186/s12888-019-2324-z